# Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

> **NCT06898515** · PHASE3 · RECRUITING · sponsor: **Reprieve Cardiovascular, Inc** · enrollment: 400 (estimated)

## Conditions studied

- Acute Decompensated Heart Failure

## Interventions

- **DEVICE:** Reprieve System
- **DRUG:** furosemide infusion

## Key facts

- **NCT ID:** NCT06898515
- **Lead sponsor:** Reprieve Cardiovascular, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898515, "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06898515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*